Heart and Lung Center Helsinki University Central Hospital, Helsinki.
Division of Cardiology, Department of Medicine, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland.
Europace. 2017 Aug 1;19(suppl_2):ii1-ii90. doi: 10.1093/europace/eux258.
The aim of this analysis was to provide comprehensive information on invasive cardiac arrhythmia therapies in the European Society of Cardiology (ESC) area over the past 10 years.
The European Heart Rhythm Association (EHRA) has collected data on invasive arrhythmia therapies since 2008. This year 53 of the 56 ESC member countries provided data for the EHRA White Book. Here we present updated data on procedure rates together with information on demographics, economy, vital statistics, local healthcare systems and training activities. Considerable heterogeneity in the access to invasive arrhythmia therapies still exists across the five geographical ESC regions. In 2016, the device implantation rates per million population were 3-6 times higher in the Western region than in the non-European and Eastern ESC member countries. Catheter ablation activity was highest in the Western countries followed by the Northern and Southern areas. In the non-European countries, atrial fibrillation ablation rate was more than tenfold lower than in the European countries. On the other hand, the growth rate over the past ten years was highest in the non-European and Eastern countries. In some Eastern European countries with relative low gross domestic product the procedure rates exceeded the average values.
It was encouraging to note that during the past decade the growth in invasive arrhythmia therapies was greatest in the areas historically with relatively low activity. Nevertheless, there is substantial disparity and continued efforts are needed to improve harmonization of cardiac arrhythmia therapies in the ESC area.
本分析旨在提供过去 10 年欧洲心脏病学会 (ESC) 地区侵袭性心脏心律失常治疗的综合信息。
欧洲心律协会 (EHRA) 自 2008 年以来一直在收集侵袭性心律失常治疗的数据。今年,56 个 ESC 成员国中有 53 个为 EHRA 白皮书提供了数据。在这里,我们提供了程序率的最新数据,以及人口统计学、经济、生命统计、当地医疗保健系统和培训活动的信息。在五个地理 ESC 区域,侵入性心律失常治疗的可及性仍然存在相当大的异质性。2016 年,西部地区每百万人的设备植入率是欧洲非成员国和东部 ESC 成员国的 3-6 倍。导管消融活动在西方国家最高,其次是北欧和南欧。在非欧洲国家,房颤消融率比欧洲国家低十倍以上。另一方面,过去十年的增长率在非欧洲和东欧国家最高。在一些相对国内生产总值较低的东欧国家,程序率超过了平均值。
令人鼓舞的是,在过去的十年中,侵袭性心律失常治疗的增长在历史上活动相对较少的地区最大。然而,仍然存在很大的差异,需要继续努力,以改善 ESC 地区心脏心律失常治疗的协调。